Thierry André, MD, Saint-Antoine Hospital, Paris, France, discusses the outcomes of the AVANT study (NCT00112918) assessing bevacizumab with oxaliplatin-based chemotherapy as adjuvant therapy for colon cancer, indicating that there may be no place for this combination in this setting for patients in stages 2 and 3. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.